Blog
RSS FeedPosted by Michael Wonder on 02 Aug 2022
Critics decry drug pricing provisions in Inflation Reduction Act, say they will stifle innovation
2 August 2022 - The push back against the prescription drug pricing provisions in the Inflation Reduction Act is relentless and ...
Posted by Michael Wonder on 02 Aug 2022
FDA official: patients play an increasing role in rare disease drug development
1 August 2022 - Patients have a critical role in drug development, from identifying unmet medical needs to assessing meaningful ...
Posted by Michael Wonder on 26 Jul 2022
Despite their anger over high drug prices, Americans are giving pharma credit for helping contain COVID-19
26 July 2022 - Nearly three quarters of Americans give the pharmaceutical industry credit for helping contain COVID-19 — and for ...
Posted by Michael Wonder on 30 Jun 2022
New strategic agreements with the medicines industry – PBS website updates
1 July 2022 - Amendments made by the National Health Amendment (Enhancing the Pharmaceutical Benefits Scheme) Act 2021 give effect to ...
Posted by Michael Wonder on 29 Jun 2022
Breaking the rule of drug pricing In America
29 June 2022 - Having worked in healthcare most of my life, very little surprises me. But four years ago, ...
Posted by Michael Wonder on 19 Jun 2022
IP waiver for COVID vaccines is a threat to future innovation
20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have ...
Posted by Michael Wonder on 19 Jun 2022
Drug pricing debate in Washington is a headache for pharma
17 June 2022 - Last-ditch effort by Democrats to pass slimmed-down version of Build Back Better could include measures on drug ...
Posted by Michael Wonder on 13 Jun 2022
IP waiver for COVID vaccines misses the mark in vaccinating the world
14 June 2022 - Vaccinating the world remains a priority and proposals to weaken the intellectual property for COVID-19 vaccines ...
Posted by Michael Wonder on 12 Jun 2022
Harvard professors continue to push misconceptions to justify drug price controls
10 June 2022 - The biopharmaceutical industry performed wonderfully during the COVID-19 pandemic. ...
Posted by Michael Wonder on 30 May 2022
Takeda says drug makers could cut prices in face of global crises
30 May 2021 - The head of Asia’s largest pharmaceutical company said the risk of a global recession, along with ...
Posted by Michael Wonder on 16 May 2022
Japan pharma lobbies say pricing scheme leading to renewed 'drug lag'
16 May 2022 - Japan's three major pharmaceutical lobbies joined for the first time on Monday in urging reforms to ...
Posted by Michael Wonder on 13 May 2022
The man behind ‘value based pricing’ saw pharma distorting his message — and walked away
13 May 2022 - When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company gave ...
Posted by Michael Wonder on 25 Apr 2022
Is it best to remove insurance benefits from drugs prescribed in bribery?
25 April 2022 - The Ministry of Health and Welfare’s Health Insurance Policy Review Committee is scheduled to hold a ...
Posted by Michael Wonder on 19 Apr 2022
Supply related data in manufacturer dossiers: things are not going smoothly yet
19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science. ...
Posted by Michael Wonder on 18 Mar 2022
Update to the statutory scheme to control the costs of branded health service medicines
15 March 2022 - The UK Government is seeking views on its proposal to increase the rate of payments made ...